|
1
|
Motzer RJ, Taylor MH, Evans TRJ, Okusaka
T, Glen H, Lubiniecki GM, Dutcus C, Smith AD, Okpara CE, Hussein Z,
et al: Lenvatinib dose, efficacy, and safety in the treatment of
multiple malignancies. Expert Rev Anticancer Ther. 22:383–400.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hao Z and Wang P: Lenvatinib in management
of solid tumors. Oncologist. 25:e302–e310. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gore E, Currey A and Choong N:
Tracheoesophageal fistula associated with bevacizumab 21 months
after completion of radiation therapy. J Thorac Oncol. 4:1590–1591.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lordick F, Geinitz H, Theisen J, Sendler A
and Sarbia M: Increased risk of ischemic bowel complications during
treatment with bevacizumab after pelvic irradiation: Report of
three cases. Int J Radiat Oncol Biol Phys. 64:1295–1298. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kozloff M, Yood MU, Berlin J, Flynn PJ,
Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A,
et al: Clinical outcomes associated with bevacizumab-containing
treatment of metastatic colorectal cancer: The BRiTE observational
cohort study. Oncologist. 14:862–870. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Basille D, Andrejak M, Bentayeb H, Kanaan
M, Fournier C, Lecuyer E, Boutemy M, Garidi R, Douadi Y and Dayen
C: Bronchial fistula associated with sunitinib in a patient
previously treated with radiation therapy. Ann Pharmacother.
44:383–386. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peters NA, Richel DJ, Verhoeff JJ and
Stalpers LJ: Bowel perforation after radiotherapy in a patient
receiving sorafenib. J Clin Oncol. 26:2405–2406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jo Y, Hiratsuka J, Fujii T, Takenaka A and
Fujisawa M: High-dose-rate iridium-192 afterloading therapy
combined with external beam radiotherapy for T1c-T3bN0M0 prostate
cancer. Urology. 64:556–560. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wachsberger P, Burd R and Dicker AP: Tumor
response to ionizing radiation combined with antiangiogenesis or
vascular targeting agents: Exploring mechanisms of interaction.
Clin Cancer Res. 9:1957–1971. 2003.PubMed/NCBI
|
|
10
|
Kleibeuker EA, Ten Hooven MA, Verheul HM,
Slotman BJ and Thijssen VL: Combining radiotherapy with sunitinib:
lessons (to be) learned. Angiogenesis. 18:385–395. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schlumberger M, Tahara M, Wirth LJ,
Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff
AO, et al: Lenvatinib versus placebo in radioiodine-refractory
thyroid cancer. N Engl J Med. 372:621–630. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ishiyama H, Kamitani N, Kawamura H, Kato
S, Aoki M, Kariya S, Matsumura T, Kaidu M, Yoshida K, Hashimoto Y,
et al: Nationwide multi-institutional retrospective analysis of
high-dose-rate brachytherapy combined with external beam
radiotherapy for localized prostate cancer: An Asian Prostate
HDR-BT Consortium. Brachytherapy. 16:503–510. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Clark BG, Souhami L, Roman TN, Chappell R,
Evans MD and Fowler JF: The prediction of late rectal complications
in patients treated with high dose-rate brachytherapy for carcinoma
of the cervix. Int J Radiat Oncol Biol Phys. 38:989–993. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakano T, Kato S, Ohno T, Tsujii H, Sato
S, Fukuhisa K and Arai T: Long-term results of high-dose rate
intracavitary brachytherapy for squamous cell carcinoma of the
uterine cervix. Cancer. 103:92–101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pollom EL, Deng L, Pai RK, Brown JM,
Giaccia A, Loo BW Jr, Shultz DB, Le QT, Koong AC and Chang DT:
Gastrointestinal toxicities with combined antiangiogenic and
stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys.
92:568–576. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zips D, Eicheler W, Geyer P, Hessel F,
Dörfler A, Thames HD, Haberey M and Baumann M: Enhanced
susceptibility of irradiated tumor vessels to vascular endothelial
growth factor receptor tyrosine kinase inhibition. Cancer Res.
65:5374–5379. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Metcalfe C, Kljavin NM, Ybarra R and de
Sauvage FJ: Lgr5+ stem cells are indispensable for
radiation-induced intestinal regeneration. Cell Stem Cell.
14:149–159. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Valerio L, Giani C, Agate L, Molinaro E,
Viola D, Bottici V, Matrone A, Puleo L, Lorusso L, Cappagli V, et
al: Prevalence and risk factors of developing fistula or organ
perforation in patients treated with lenvatinib for
radioiodine-refractory thyroid cancer. Eur Thyroid J. 10:399–407.
2021. View Article : Google Scholar : PubMed/NCBI
|
